Vertex Pharmaceuticals (NASDAQ:VRTX) Announces Quarterly Earnings Results

Vertex Pharmaceuticals (NASDAQ:VRTX) released its quarterly earnings data on Monday. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45), Zacks reports. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Vertex Pharmaceuticals updated its FY 2025 guidance to EPS.

Vertex Pharmaceuticals Trading Down 3.1 %

Shares of NASDAQ VRTX opened at $455.22 on Wednesday. The firm has a fifty day moving average of $435.95 and a 200 day moving average of $462.13. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several research reports. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Citigroup initiated coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $575.00 target price on the stock. UBS Group increased their target price on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday. Ten investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $505.29.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.